NCT04910295View on ClinicalTrials.gov

Immunogenicity and Safety of COVID-19 Vaccine in Cancer Patients

CompletedOBSERVATIONAL
Enrollment

112

Participants

Timeline

Start Date

March 26, 2021

Primary Completion Date

April 30, 2022

Study Completion Date

December 31, 2022

Conditions
CancerCovid19
Interventions
DRUG

COVID-19 vaccine

Subjects will be vaccinated with COVID-19 vaccines approved in Korea. Data on specific vaccines will be gathered.

Trial Locations (1)

03080

Seoul National University Hospital, Seoul

All Listed Sponsors
lead

Seoul National University Hospital

OTHER

NCT04910295 - Immunogenicity and Safety of COVID-19 Vaccine in Cancer Patients | Biotech Hunter | Biotech Hunter